je.st
news
Data on Mercks Pembrolizumab from Largest Study to Date of Investigational Anti-PD-1 Antibody in Advanced Melanoma Highlighted at ASCO 2014
2014-06-02 13:30:00| Merck.com - Corporate News
Dateline City: CHICAGO Pembrolizumab as Monotherapy Shows Estimated Overall Survival Rate of 69 Percent at One Year Across 411 Advanced Melanoma Patients with Varying Stages of Disease and Prior Therapy Durable Responses and Consistent Tolerability Profile Observed Across Doses, Including Patients With or Without Prior Ipilimumab Therapy Phase 3 Trials Ongoing or Planned Across Lines of Therapy, Including Adjuvant Treatment CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data from the companys large ongoing Phase 1b study (KEYNOTE-001) evaluating pembrolizumab (MK-3475), Mercks investigational anti-PD-1 antibody, as a single agent (monotherapy) in 411 patients with advanced melanoma. Language: English Contact: MerckMedia:Ian McConnell, 973-901-5722orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: date
data
advanced
study
Category:Biotechnology and Pharmaceuticals